Tear protein biomarkers of refractive surgery pain

项目总结 准分子激光屈光性角膜切削术(PRK)和准分子激光原位角膜磨镶术(LASIK) 用于矫正屈光不正的外科手术，约有60万例 每年在美国演出。一个比例(10%-20%)的个体发育 屈光手术后持续的眼痛，这是一个巨大的发病率来源， 限制工作能力，影响心理健康，严重时导致自杀意念 案子。我们假设泪液中的蛋白质调节角膜神经功能， 增加屈光手术后持续性疼痛的风险并促进其发生。因此，我们的 研究将使用术后泪液的蛋白质组学分析来确定诊断生物标志物 持续的眼部疼痛。我们还将在手术前检测泪液蛋白，以努力确定 预测哪些人可能在术后发生持续性疼痛的预后生物标志物 做手术。R33阶段研究将使用替代蛋白质组学平台进行分析验证， 和额外的新患者群体进行临床验证。这一知识可以导致 更好的预防和治疗算法来对抗这种虚弱的疾病，因此 提高生活质量，减少患者痛苦。

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.